Nothing Special   »   [go: up one dir, main page]

GB0809821D0 - Treatment and diagnosis of behavioural disorders - Google Patents

Treatment and diagnosis of behavioural disorders

Info

Publication number
GB0809821D0
GB0809821D0 GBGB0809821.2A GB0809821A GB0809821D0 GB 0809821 D0 GB0809821 D0 GB 0809821D0 GB 0809821 A GB0809821 A GB 0809821A GB 0809821 D0 GB0809821 D0 GB 0809821D0
Authority
GB
United Kingdom
Prior art keywords
treatment
diagnosis
behavioural
behavioural disorders
eif4e
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0809821.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Grampian Health Board
Original Assignee
University of Aberdeen
Grampian Health Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen, Grampian Health Board filed Critical University of Aberdeen
Priority to GBGB0809821.2A priority Critical patent/GB0809821D0/en
Publication of GB0809821D0 publication Critical patent/GB0809821D0/en
Priority to GB1021794.1A priority patent/GB2473575B/en
Priority to PCT/GB2009/001367 priority patent/WO2009144480A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention concerns the identification of a novel drug target for use in the treatment of behavioural dis order, hi particular, the invention provides compounds capable of modulating the expression, function and/or activity of eIF4E, for use in treating a behavioural disorder as well as methods of identifying the same.
GBGB0809821.2A 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders Ceased GB0809821D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0809821.2A GB0809821D0 (en) 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders
GB1021794.1A GB2473575B (en) 2008-05-30 2009-05-29 Diagnosis of autism
PCT/GB2009/001367 WO2009144480A1 (en) 2008-05-30 2009-05-29 Treatment and diagnosis of behavioural disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0809821.2A GB0809821D0 (en) 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders

Publications (1)

Publication Number Publication Date
GB0809821D0 true GB0809821D0 (en) 2008-07-09

Family

ID=39637839

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0809821.2A Ceased GB0809821D0 (en) 2008-05-30 2008-05-30 Treatment and diagnosis of behavioural disorders
GB1021794.1A Expired - Fee Related GB2473575B (en) 2008-05-30 2009-05-29 Diagnosis of autism

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1021794.1A Expired - Fee Related GB2473575B (en) 2008-05-30 2009-05-29 Diagnosis of autism

Country Status (2)

Country Link
GB (2) GB0809821D0 (en)
WO (1) WO2009144480A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166029A1 (en) 2009-09-08 2011-07-07 David Michael Margulies Compositions And Methods For Diagnosing Autism Spectrum Disorders
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
WO2017176813A1 (en) * 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
US11345911B2 (en) 2017-04-17 2022-05-31 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2A-P pathways
US11903910B2 (en) 2017-09-26 2024-02-20 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
WO2021067752A1 (en) * 2019-10-04 2021-04-08 Yale University Targeting cap-dependent translation to reduce seizures in mtor disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094755A2 (en) * 2005-02-04 2007-08-23 Massachusetts Institute Of Technology Compositions and methods for modulating cognitive function

Also Published As

Publication number Publication date
WO2009144480A1 (en) 2009-12-03
GB2473575A (en) 2011-03-16
GB201021794D0 (en) 2011-02-02
GB2473575B (en) 2013-02-20

Similar Documents

Publication Publication Date Title
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
UA107667C2 (en) Medical compounds stimulating activity of pyruvate kinase m2, compositions on their basis and use in the treatment of cancer
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
BRPI0813311A2 (en) COMPOUND, METHODS FOR MODULATING THE ACTIVITY OF A PROTEIN KINASE AND FOR TREATING CANCER IN AN INDIVIDUAL AND PHARMACEUTICAL COMPOSITION.
UA109878C2 (en) Isoquinolinone derivatives, pharmaceutical composition based on them (variants), and method of treating diseases (variants)
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
WO2012062925A3 (en) Compounds and methods for treating pain
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2007117344A3 (en) Differentiating and/or identifying tissue regions innervated by targeted nerves
BR112018007026A2 (en) compound, gaba-at activity modulation method, dopamine level modulation method, substance dependence treatment method, ornithine aminotransferase activity modulation method, ornithine aminotransferase activity reduction method expressed by a human hepatocellular carcinoma and method for treating psychological and neurological disorders
WO2008086025A3 (en) Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2010034015A3 (en) Modulating the alternative complement pathway
EA201370008A1 (en) TREATMENT OF COGNITIVE DISTURBANCES
UY33276A (en) AMINO-OXAZINES AND AMINO-DIHYDROTIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
GB2473575A (en) Treatment and diagnosis of behavioural disorders
HK1209035A1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
BR112012009121A2 (en) NEW COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
MY155340A (en) Use of cathepsin c
MX2009009693A (en) Methods of activating irs-1 and akt.
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
EP1898950A4 (en) Galk1s as modifiers of the pten/akt pathway and methods of use
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)